Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of apatinib for advanced gastric cancer
ChiCTR1800017789Phase 4Not yet recruiting
- Sponsor
- Zhejiang Provincial Hospital of Traditional Chinese Medicine
- Start
- Aug 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Zhejiang Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: progression-free survival. Planned start Aug 2018; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR1800017789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017789.